Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A
dc.contributor.author | Gupta, A. K. | en_US |
dc.contributor.author | Cooper, Kevin D. | en_US |
dc.contributor.author | Ellis, Charles N. | en_US |
dc.contributor.author | Baadsgaard, Ole | en_US |
dc.contributor.author | Voorhees, John J. | en_US |
dc.date.accessioned | 2006-09-11T18:45:08Z | |
dc.date.available | 2006-09-11T18:45:08Z | |
dc.date.issued | 1989-07 | en_US |
dc.identifier.citation | Gupta, A. K.; Baadsgaard, O.; Ellis, C. N.; Voorhees, J. J.; Cooper, K. D.; (1989). "Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A." Archives of Dermatological Research 281(4): 219-226. <http://hdl.handle.net/2027.42/47242> | en_US |
dc.identifier.issn | 0340-3696 | en_US |
dc.identifier.issn | 1432-069X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47242 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2673064&dopt=citation | en_US |
dc.description.abstract | Since cyclosporin A (CsA) is an immuno-suppressive agent, its beneficial effect in psoriasis suggests that immune cells may play a role in the pathogenesis and resolution of psoriasis. To determine early effects of CsA in psoriasis, we quantitated immune cells using double immunofluorescence microscopy on biopsy specimens obtained prior to therapy and after 3,7, and 14 days of CsA therapy. CsA therapy resulted in significant reductions in the absolute number of immune cells (including T cells, monocytes/macrophages, and antigen presenting cells) contained within psoriatic skin. The effect was rapid, with over one-half of the reduction in the density of HLe1 + (human leukocyte antigen-1 positive or bone marrow derived) cells, including T cells, activated T cells, monocytes, and Langerhans cells (LCs), occurring within 3 days. Despite the overall reduction in the numbers of immunocytes in the skin, the proportion of T cells, Langerhans cells, and monocytes in relation to the total number of immune cells was unchanged with therapy, reflecting equally proportional losses of each subtype. Dermal CD1 + DR + cells (putative Langerhans cells), which are not found in normal skin but are present in lesional psoriasis skin, were virtually cleared from the papillary dermis after CsA therapy. Although absolute numbers of epidermal Langerhans cells, defined as cells expressing both CD1 (T6) and DR molecules (CD1 + DR + ), were also reduced after CsA, epidermal non-Langerhans CD1 - DR + cells (macrophages, activated T cells, DR - keratinocytes) demonstrated a proportionally greater decrease, with the ratio of CD1 + DR + Langerhans cells/non-Langerhans CD1 - DR + epidermal cells changing from a mean of 0.82 at baseline to 1.92 at day 14. Thus, early in the course of therapy, CsA appears to be effective at clearing CD1 - DR + cells while leaving LC relatively intact in the epidermis. | en_US |
dc.format.extent | 832937 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Langerhans Cells | en_US |
dc.subject.other | Cyclosporin A | en_US |
dc.subject.other | Dermatology | en_US |
dc.subject.other | Monoclonal Antibodies | en_US |
dc.subject.other | Monocytes | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Antigen Presenting Cells | en_US |
dc.subject.other | Psoriasis | en_US |
dc.subject.other | T Cells | en_US |
dc.title | Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Dermatology, Immunodermatology Unit, University of Michigan Medical Center, Kresge I R5538, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Dermatology, Immunodermatology Unit, University of Michigan Medical Center, Kresge I R5538, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Dermatology, Immunodermatology Unit, University of Michigan Medical Center, Kresge I R5538, 48109, Ann Arbor, Michigan, USA; Dermatology Service, Ann Arbor Veterans Administration Hospital, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Dermatology, Immunodermatology Unit, University of Michigan Medical Center, Kresge I R5538, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Dermatology, Immunodermatology Unit, University of Michigan Medical Center, Kresge I R5538, 48109, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2673064 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47242/1/403_2004_Article_BF00431054.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00431054 | en_US |
dc.identifier.source | Archives of Dermatological Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.